


MicroRNAs: novel regulators in skin research

Eniko Sonkoly, Andor Pivarcsi

KI, Department of Medicine, Unit of Dermatology and Venerology

What are microRNAs?


- Small, ~21-mer RNAs
- 1993: The first miRNA discovered, Lin-4, regulated the developmental transitions in *Caenorhabditis elegans*
- The second microRNA was discovered 7 years later (2000)
- Today (October, 2008) we know more than **8000 miRNAs** (miRBase 12.0)
- The most abundant regulators of gene expression in the genome!



Lee et al., *Cell*, 1993
Sonkoly et al, *J Cell Mol Med*, in press


MicroRNAs: regulators of gene expression

- Regulate the expression of most protein-coding genes
- MicroRNAs inhibit gene expression at the post-transcriptional level
- Their function and importance can be compared to transcription factors
- Regulate basic biological processes
 - Apoptosis
 - Morphogenesis
 - Proliferation
 - Metabolism
 - Signal transduction
 - Determination of cell fate
 - Developmental timing




MicroRNA biogenesis and mode of action

- Encoded in the genome
- Transcribed from DNA as pri-microRNA
- Processed into pre-microRNA in the cell nucleus
- In the cytoplasm they are processed into the mature microRNA
- Mature microRNA form complexes with the 3' UTR (untranslated region) of target mRNA and
- Suppress their translation/induce their degradation



The emergence of miRNAs will not make the understanding of regulatory networks easier...


- Each miRNA regulates more than one gene
- Each gene is regulated by more than one miRNA
- Many miRNA targets are transcription factors – miRNAs regulate the regulators
- MiRNA expression is regulated by transcription factors
- The potential regulatory effect of miRNAs is enormous



Modified from George Calin, MD PhD


Abnormal miRNA expression can cause diseases

- Altered miRNA expression was first implicated in cancers
- MiRNAs may act as
 - tumor suppressors (i.e. miR-16, let-7s)
 - oncogenes (i.e. miR-155, miR-21)
- MiRNAs regulate proliferation, apoptosis and angiogenesis
- In the past few years miRNAs have also been implicated in developmental and metabolic diseases



Why study the skin?


- The largest organ (Surface area 1.5 - 2 m²; ~9 kg)
- Common and severe diseases
 - Inflammatory diseases (psoriasis, atopic eczema)
 - Tumors (BCC, SCC)
 - Genetic disorders (Xeroderma pigmentosum, ichthyosis)
 - Bullosus
- A handy model for other diseases
 - Easily accessible
 - Skin Immune System (SIS) – Inflammation
 - Carcinogenesis
 - Morphogenesis



Do microRNAs have a role in psoriasis?

- Is there a set of microRNAs that distinguishes healthy skin from psoriasis skin?
- If yes, which are those microRNAs?
- Does microRNA deregulation play a role in psoriasis?


Healthy skin




miRNAs?



Psoriasis








Psoriasis has a specific microRNA expression profile



- Genome-wide analysis of miRNA expression using an array with LNA probes showed that:
 - A set of microRNAs is expressed in human skin
 - Healthy skin, atopic eczema lesion and psoriatic lesions display **distinct microRNA expression profiles**

miR-203 is specifically overexpressed in psoriasis


Psoriasis			Atopic eczema		
miRNA	Score	Fold change	miRNA	Score	Fold change
miR-146b	4.68	3.31	let-7f	2.50	2.04
miR-20a	4.08	2.90	miR-29a	2.39	1.83
miR-146a	4.05	3.30	miR-146a	2.35	2.22
miR-31	3.47	4.69	miR-222	2.22	1.67
miR-200a	2.85	2.75	miR-24	2.20	1.85
miR-17-5p	2.67	3.77	miR-193a	2.14	2.27
miR-30e-5p	2.61	3.61	miR-199a	2.13	1.72
miR-141	2.26	3.45	miR-27a	2.04	1.72
miR-203	2.23	5.86	miR-21	2.04	3.26
miR-142-3p	2.22	2.55	miR-20a	2.02	2.35
miR-21	2.21	2.51	miR-17-5p	1.82	2.58
miR-106a	2.16	2.37	miR-106b	1.78	1.72
miR-125b	-5.31	0.55	miR-122a	-2.75	0.19
miR-99b	-3.32	0.58	miR-133a-133b	-2.73	0.28
miR-122a	-3.09	0.18	miR-326	-2.50	0.39
miR-197	-2.69	0.64	miR-215	-2.48	0.42
miR-100	-2.62	0.59	miR-483	-1.89	0.57
miR-381	-2.60	0.71	miR-519d	-1.86	0.48
miR-518b	-2.55	0.56	miR-335	-1.78	0.63
miR-524	-2.40	0.50	miR-133b	-1.68	0.23
let-7e	-2.25	0.60	miR-515-5p	-1.57	0.43
miR-30c	-1.98	0.63			
miR-365	-1.87	0.62			
miR-133b	-1.78	0.22			
miR-10a	-1.78	0.67			
miR-133a-133b	-1.76	0.40			
miR-22	-1.68	0.61			
miR-326	-1.61	0.56			
miR-215	-1.59	0.56			



- **miR-203** and miR-146a are overexpressed in psoriasis but not in atopic eczema
- miR-21 is overexpressed and **miR-125b** is suppressed in both diseases
- miR-146 and miR-125b was recently implicated in the regulation of TLR-signaling
- miR-203: potential functions - unknown



miR-203 is a skin-specific microRNA

- Highest expression in the skin
- Also expressed in the esophagus
- A role in the differentiation of squamous epithelia?








miR-203 is a keratinocyte-specific microRNA

- Keratinocyte-specific expression
- Higher expression in the upper, more differentiated cell layers
- Increased expression in the epidermis of psoriasis lesions




Sonkoly et al., PLoS ONE, 2007

miR-203 is regulated during differentiation



Downloaded from <http://ajph.org/> on November 10, 2015




-





What is the relevance to cosmetics?

- Potential applications



SUMMARY



- microRNA expression patterns distinguish psoriasis from healthy skin and atopic eczema
- miR-203 is a skin- and keratinocyte-specific microRNA
- Its up-regulation in psoriasis is concurrent with the down-regulation of its target, SOCS-3
- a new layer of regulatory mechanisms is involved in the pathogenesis of chronic inflammatory skin diseases

Acknowledgements

Eniko Sonkoly

Tianling Wei

Mona Ståhle

Molecular Dermatology Research Group,
Dermatology and Venerology Unit,
CMM, Karolinska Institutet, Sweden

Annika Sääf

Gunnar Norstedt

Dept. of Molecular Medicine and Surgery,
CMM, Karolinska Institutet, Sweden

Elizabeth Pavez Lorie

Hans Törmä

Dept. Of Dermatology,
Uppsala University, Sweden

Lena Lundeberg

Maria Tengvall-Linder

Annika Scheynius

Dermatology and Venerology Unit,
Clinical Allergy Research Unit,
Karolinska Institute, Sweden

Peter C. Janson

Ola Winquist

Clinical Allergy Research Unit,
Karolinska Institute, Sweden

Bernhard Homey

Dept. Of Dermatology
Heinrich-Heine University
Dusseldorf, Germany

Harri Alenius

Finnish Institute of Occupational Health
Helsinki, Finland

Contact info:

Eniko.Sonkoly@ki.se

Andor.Pivarcsi@ki.se